Dataset Information

Next-Generation Sequencing Facilitates Quantitative Analysis of Control and BET bromodomain Inhibitor-treated Uterine Leiomyosarcoma Cell Transcriptome

ABSTRACT: Next-Generation Sequencing Facilitates Quantitative Analysis of Control and BET bromodomain Inhibitor-treated Uterine Leiomyosarcoma Cell Transcriptome

PROVIDER: PRJNA1149078 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	SRR30276872_1.fastq.gz	Fastqsanger.gz
	SRR30276872_2.fastq.gz	Fastqsanger.gz
	SRR30276873_1.fastq.gz	Fastqsanger.gz
	SRR30276873_2.fastq.gz	Fastqsanger.gz
	SRR30276874_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Project description:Objective: The objective of this study was to estimate the accuracy of transcriptome-based classifier in differential diagnosis of uterine leiomyoma and leiomyosarcoma. Methods: We manually selected 114 normal uterine tissue and 31 leiomyosarcoma samples from publicly available transcriptome data in UCSC Xena as training/validation sets. We developed pre-processing procedure and gene selection method to sensitively find genes of larger variance in leiomyosarcoma than normal uterine tissues. Through our method, twenty genes were selected to build transcriptome-based classifier. The prediction accuracies of deep feedforward neural network (DNN), support vector machine (SVM), Random Forest (RF), and Gradient Boosting (GB) models were examined. We interpret the biological functionality of selected genes via network-based analysis using Gene-Mania. To validate the performance of trained model, we additionally collected 35 clinical samples of leiomyosarcoma and leiomyoma as a test set (18 + 17 as 1st and 2nd test sets). Results: We discovered genes expressed in a highly variable way in leiomyosarcoma while these genes are expressed in a conserved way in normal uterine samples. These genes were mainly associated with DNA replication, cell cycle, and DNA damage checkpoint. Among evaluated machine learning classifiers, the DNN had the highest accuracy and average AUC value in training data set. As gene selection and model training were made in leiomyosarcoma and uterine normal tissue, proving discriminant of ability between leiomyosarcoma and leiomyoma is necessary. Thus, further validation of trained model was conducted in newly collected clinical samples of leiomyosarcoma and leiomyoma. The DNN classifier performed AUC of 0.917 and 0.914 supporting that the selected genes in conjunction with DNN classifier are well discriminating the difference between leiomyosarcoma and leiomyoma in clinical sample. Conclusion: The transcriptome-based classifier accurately distinguished uterine leiomyoma from leiomyosarcoma.

Dataset Information

Next-Generation Sequencing Facilitates Quantitative Analysis of Control and BET bromodomain Inhibitor-treated Uterine Leiomyosarcoma Cell Transcriptome

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets